Semaglutide

Semaglutide is a synthetic analog of the human hormone GLP-1, designed for prolonged action with once-weekly subcutaneous injection or once-daily oral administration Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery. It was first approved as Ozempic (injectable) for type 2 diabetes in 2018 and later as Rybelsus (oral), the first oral GLP-1 receptor agonist, made possible by co-formulation with the absorption enhancer SNAC Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery+1.

Beyond glucose control, semaglutide consistently reduces body weight and has been shown in large randomized trials to lower the risk of major adverse cardiovascular events and slow kidney disease progression in people with type 2 diabetes and chronic kidney disease Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis+2. These benefits have led to additional FDA approvals for cardiovascular risk reduction and a renal indication A Renal Indication for Semaglutide (Ozempic)+2.

Semaglutide mimics the natural hormone GLP-1 but lasts much longer in the body, enabling once-weekly dosing for the injectable form Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis. It binds to and activates GLP-1 receptors found on pancreatic beta cells, in the gut-brain axis, and in other tissues Three-year changes in renal function after switching from injectable GLP-1 receptor agonists to oral semaglutide in Japanese patients with type 2 diabetes: a retrospective cohort study+2.

In the pancreas, this binding amplifies glucose-dependent insulin secretion, meaning insulin is released only when blood sugar is high, reducing the risk of hypoglycemia Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis+2. At the same time, glucagon secretion is lowered, further improving blood glucose levels Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis.

Semaglutide also acts in the brain, directly activating appetite-regulating neurons in the hypothalamus. In laboratory models, it increased firing of neurons that promote satiety, helping to reduce hunger and food intake Three-year changes in renal function after switching from injectable GLP-1 receptor agonists to oral semaglutide in Japanese patients with type 2 diabetes: a retrospective cohort study+1. This central effect, together with a delay in stomach emptying, leads to earlier fullness and smaller meal sizes Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis+2.

The oral formulation uses the absorption enhancer SNAC, which creates temporary openings in the stomach lining that allow the large peptide molecule to enter the bloodstream Permeation enhancer-induced membrane defects assist the oral absorption of peptide drugs.

In clinical trials, semaglutide consistently lowers HbA1c (a measure of average blood sugar) and reduces body weight Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis+2. For people with type 2 diabetes, reductions of 1–2 percentage points in HbA1c are common, while weight loss typically ranges from 5% to over 15% depending on dose and duration Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the <scp>SUSTAIN</scp> and <scp>PIONEER</scp> Clinical Trials+1.

Large meta-analyses have confirmed that semaglutide protects the heart and blood vessels. It reduced the risk of major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by about 29% compared to placebo or other treatments Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis. In people with type 2 diabetes and chronic kidney disease, GLP-1 receptor agonists as a class (including semaglutide) lowered the risk of kidney function worsening and cardiovascular death Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis+1.

Real-world data also show improvements in blood pressure, cholesterol levels, and quality of life scores Semaglutide <scp>2.4 mg</scp> Cardiometabolic Long‐Term Effects in Patients With Obesity or Overweight in a Real‐World Setting: A Retrospective Cohort Study in the United States ( <scp>SMILE</scp> )+1. The most common documented side effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, particularly when starting or increasing the dose Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis+1.

Research protocols with semaglutide follow a gradual dose escalation to allow the body to adapt to slowed stomach emptying and appetite changes. The standard approach is to start low and increase the dose every 4 weeks based on tolerability Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis+1.

For subcutaneous injection, common starting dose is 0.25 mg once weekly for 4 weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg as the target maintenance dose for weight management Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis+1. In type 2 diabetes, many people achieve adequate glucose control at 0.5–1.0 mg per week Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the <scp>SUSTAIN</scp> and <scp>PIONEER</scp> Clinical Trials.

The oral formulation is taken once daily on an empty stomach with a small sip of water, followed by a 30-minute wait before food or other drinks Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery+1. Typical titration is 3 mg daily for 30 days, then 7 mg, then 14 mg if further control is needed. A 25 mg daily oral dose is being studied for obesity and may produce effects similar to injectable 2.4 mg Efficacy, Safety and <scp>PK</scp> of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach.

Individual response varies, and slower escalation is often used in practice to minimize gastrointestinal side effects. Because semaglutide’s effects on weight are dose-dependent, reaching a higher maintenance dose is usually necessary for substantial appetite suppression Efficacy, Safety and <scp>PK</scp> of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach.

Commercial semaglutide comes in ready-to-use injection pens or tablets that require no mixing or reconstitution Comparison of the injection‐site experience of semaglutide in a single‐dose and a multidose pen‐injector+1. These products should be stored according to the manufacturer’s instructions, typically under refrigeration before first use and at controlled room temperature thereafter for a limited time.

Compounded or non-branded semaglutide obtained from unregulated sources carries significant risks, including dosing errors, contamination, and substitution with other substances Falsified batches of OZEMPIC (semaglutide) identified+2. Cases of falsified semaglutide containing insulin have been reported, leading to severe hypoglycemia Hypoglycaemic coma induced by a falsified semaglutide product: a case report+1. For these reasons, handling and storage of non-commercial preparations cannot be standardized, and their stability is uncertain.

If a research setting requires preparation from a lyophilized vial, careful attention to sterility, accurate measurement of diluent volume, and proper refrigeration are critical. However, detailed reconstitution instructions fall outside the scope of this reference because semaglutide is not authorized for such use.

Semaglutide slows stomach emptying, which can affect how other oral medications are absorbed. This is most important for drugs that need exact timing or steady blood levels, such as thyroid hormone (levothyroxine), warfarin, epilepsy medications, and immunosuppressants GLP-1 agonists: A review for emergency clinicians+1. These should be taken at a different time than oral semaglutide, and monitoring is advised.

When combined with insulin or sulfonylureas, the risk of low blood sugar increases because both treatments lower glucose GLP-1 agonists: A review for emergency clinicians. Doses of these companion drugs may need to be reduced when starting semaglutide.

Semaglutide can cause dehydration if nausea and vomiting are severe. In such cases, taking diuretics, ACE inhibitors, or NSAIDs may raise the risk of kidney injury temporarily GLP-1 agonists: A review for emergency clinicians+1. Using sick-day rules (holding certain medications during vomiting or poor fluid intake) is often recommended.

Before surgery or procedures requiring sedation, semaglutide’s delay in stomach emptying can leave food in the stomach even after fasting, increasing the chance of aspiration. Many guidelines suggest holding weekly semaglutide for at least 7 days before elective procedures Anesthesia and glucagon-like peptide-1 receptor agonists: proceed with caution!+1.

Combining semaglutide with other GLP-1 agonists (like tirzepatide or liraglutide) is generally avoided because the mechanisms overlap and gastrointestinal side effects add up without clear extra benefit.

Semaglutide is designed for continuous use. In trials lasting over a year, benefits in weight and glucose control persisted only while treatment continued; stopping usually leads to weight regain and loss of glycemic improvements Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in <scp>F</scp> inland+1. Therefore, a fixed on‑off cycle is not supported by evidence, unless side effects or planned procedures require a break.

Some people pause semaglutide for a few weeks to manage side effects, reduce cost, or prepare for surgery. In these cases, restarting is typically done at a low dose (0.25 mg weekly) and re-escalated slowly, because gastrointestinal tolerance is often lost after a break GLP-1 agonists: A review for emergency clinicians+1.

If a high dose is no longer needed for maintenance, the dose may be dialed down rather than stopped completely. Practitioners sometimes reduce to the lowest dose that still controls appetite and weight, which can be 0.5–1.0 mg weekly. However, no formal tapering protocol has been studied in large trials.

Semaglutide should not be combined with other GLP-1 receptor agonists, including tirzepatide (which also activates GLP-1 receptors), because mechanisms overlap and gastrointestinal side effects would likely be additive without additional benefit GLP-1 agonists: A review for emergency clinicians.

Combining semaglutide with peptides that work through different pathways, such as BPC-157 or growth hormone secretagogues, has no known direct interaction. However, the appetite-suppressing effects of semaglutide may make it harder to eat enough to support muscle building if one is also using anabolic agents Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs).

Adding an amylin analog like cagrilintide may enhance satiety and weight loss further, but this combination is still investigational and should only be done in structured research settings.

In general, stacking multiple weight-modifying compounds raises the risk of dehydration, malnutrition, and unpredictable side effects. Careful monitoring of hydration status and food intake is necessary.

Semaglutide is FDA approved in the United States under several brand names: Ozempic for type 2 diabetes and kidney disease, Wegovy for chronic weight management and cardiovascular risk reduction, and Rybelsus (oral) for type 2 diabetes and cardiovascular risk reduction A Renal Indication for Semaglutide (Ozempic)+2. It is not a controlled substance and is not scheduled by the DEA.

In Europe, semaglutide has been authorized by the EMA since 2018 for diabetes and later for obesity. It is also approved in the United Kingdom, Australia, Canada, and many other countries The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis+1.

Compounded versions are sometimes available when brand-name products are in shortage, but they are higher risk due to variable quality and authenticity concerns Navigating compounded semaglutide: what health care providers need to know+1. The FDA has issued warnings against counterfeit Ozempic, and batches of falsified product have been found in several regions Falsified batches of OZEMPIC (semaglutide) identified+1.

Semaglutide is not listed as a banned substance by WADA, so it is permitted in sports, but athletes should keep documentation of their prescription and source to avoid inadvertent doping violations from contaminated products Falsified Ozempic (semaglutide) and Saxenda (liraglutide).

The most common side effects with semaglutide are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These occur in up to 20% of people, especially during dose increases, but often improve with time Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review+1. Staying hydrated and eating smaller, lower-fat meals can help.

More serious but less common risks include pancreatitis, gallbladder disease, and acute kidney injury, often triggered by severe vomiting and dehydration GLP-1 agonists: A review for emergency clinicians+1. Because semaglutide delays stomach emptying, there is a risk of food remaining in the stomach before surgery, which can lead to aspiration pneumonia. Informing an anesthesiologist and stopping the drug for at least a week before elective procedures is standard practice Anesthesia and glucagon-like peptide-1 receptor agonists: proceed with caution!.

In people with diabetes, rapid improvement in blood sugar can temporarily worsen diabetic retinopathy, so eye exams are recommended before starting and during treatment Semaglutide increases risk of diabetic retinopathy in older patients+1. There have been rare post-marketing reports of depressed mood, suicidal thoughts, and hair loss, but a causal link has not been proven Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study+1.

Semaglutide should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, based on animal studies Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. It is also not recommended during pregnancy or breastfeeding due to limited safety data.